UK Markets close in 4 hrs 19 mins

ObsEva SA (OBSV)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.1860-0.0037 (-1.95%)
At close: 04:00PM EST
0.1840 -0.00 (-1.08%)
Pre-market: 07:00AM EST

ObsEva SA

Chemin des Aulx, 12
Plan-les-Ouates
Geneva 1228
Switzerland
41 22 552 38 40
https://www.obseva.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees48

Key executives

NameTitlePayExercisedYear born
Mr. Brian O'CallaghanCEO & Director1.12MN/A1969
Dr. Ernest Loumaye M.D., OB/GYN, Ph.D.Co-Founder & Director62kN/A1952
Mr. Fabien Lefebvre de LadonchampsChief Admin. OfficerN/AN/A1979
Mr. Clive BertramChief Commercial OfficerN/AN/A1968
Mr. Luigi MarroChief Transformation OfficerN/AN/A1966
Mr. William Michael BrownChief Financial OfficerN/AN/A1983
Ms. Delphine RenaudPersonal Assistant to the CSO and Head of R&DN/AN/AN/A
Ms. Katja BuhrerChief Strategy OfficerN/AN/A1982
Ms. Brandi Howard Ph.D.Chief Clinical OfficerN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ObsEva SA, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin releasing hormone receptor antagonist that is in Phase III clinical trial for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women. The company is also involved in developing Ebopiprant, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, which is in Phase II clinical trial as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age; and Nolasiban, an oral oxytocin receptor antagonist that is in Phase I clinical trial to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.

Corporate governance

ObsEva SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.